Revolution Medicines reports Phase 3 RASolute 302 results showing daraxonrasib significantly improves overall survival in previously treated metastatic pancreatic cancer patients.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Revolution Medicines has reported positive topline results from its global Phase 3 RASolute 302 trials, demonstrating that the investigational agent daraxonrasib significantly improves survival outcomes in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Survival Outcomes Show Clear Clinical Benefit
In the randomized, controlled study, once-daily oral daraxonrasib achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared with standard intravenous cytotoxic chemotherapy. Median OS reached 13.2 months versus 6.7 months with chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The therapy was generally well tolerated, with a manageable safety profile and no new safety signals reported.
Mechanism Targets RAS-Driven Disease Biology
Daraxonrasib is a multi-selective inhibitor of RAS(ON) proteins, a central driver in many cancers. More than 90% of patients with Pancreatic Cancer harbor tumors driven by RAS mutations. The therapy is designed to inhibit both mutant and wild-type RAS signaling, enabling broad targeting across oncogenic variants.
Trial Design and Patient Population
The RASolute 302 trial (NCT06625320) enrolled patients with metastatic PDAC harboring a wide range of RAS mutations, including G12 variants, as well as those without identifiable RAS mutations. Primary endpoints evaluated PFS and OS in patients with RAS G12 mutations, while secondary endpoints assessed outcomes in the overall intent-to-treat population. Based on the first interim analysis, all PFS and OS results are considered final.
Investigator Highlights Practice-Changing Potential
Principal investigator Brian M. Wolpin of Dana-Farber Cancer Institute stated that the findings represent a meaningful advance for patients who have progressed on prior therapies. He indicated that the observed survival benefit could influence clinical practice and improve treatment outcomes in this setting.
Company Emphasizes Transformative Impact
Mark A. Goldsmith, chairman and CEO of Revolution Medicines, noted that the trial demonstrated a substantial survival improvement consistent with earlier findings. He added that the results support the company’s strategy of targeting RAS-driven cancers and reinforce its commitment to advancing regulatory submissions globally.
Regulatory Pathway and Upcoming Data Presentation
The company plans to submit these data to global regulatory authorities, including the U.S. Food and Drug Administration, and present detailed findings at the American Society of Clinical Oncology Annual Meeting 2026. Daraxonrasib has received Breakthrough Therapy and Orphan Drug designations for PDAC with G12 mutations and has been selected for the FDA Commissioner’s National Priority Voucher program.
High Unmet Need in Metastatic PDAC
Metastatic PDAC remains one of the most lethal malignancies, often diagnosed at advanced stages and associated with a five-year survival rate of approximately 3%. Limited treatment options and resistance to chemotherapy continue to drive the need for effective targeted therapies.
Reference
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.